Tecentriq Triple Combo Under FDA Review for NSCLC Treatment
Genetech has announced that the U.S. Food and Drug Administration (FDA) will be reviewing its Tecentriq (atezolizumab) combined with chemotherapy drugs Abraxane (nab-paclitaxel) and carboplatin for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The drug will be for patients without any mutations in the EGFR and ALK genes. Tecentriq is a checkpoint inhibitor drug that targets […]
Continue readingOutPatient Program CHIPSA Hospital Review: Rachael M.
Rachael Came to CHIPSA Seeking an Alternative Treatment as she had been diagnosed with stage 3 Colon Cancer. In this review, Rachel talks about her experience as part of the outpatient program at CHIPSA Hospital. – “I had enough of conventional medicine and I did not want to be sick any more” If you […]
Continue reading